Perceptive Advisors CRVS Position
Active5-Fund ConvergencePerceptive Advisors trimmed their position in Corvus Pharmaceuticals Inc. (CRVS) in Q4 2025, holding $5.3M worth of shares across 692,441 shares.
The position was first reported in Q2 2025 and has been tracked across 3 quarterly 13F filings.
CRVS is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Soquelitinib in 440 days (Jun 30, 2027), making the timing of Perceptive's position particularly relevant.
Short interest stands at 23.5% of float with 13.4 days to cover, indicating significant bearish positioning against Perceptive's long thesis.
About Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Full company profile →Short Interest
23.5%
13.4 days to cover
Perceptive Advisors CRVS Position History
Frequently Asked Questions
Does Perceptive Advisors own CRVS?
Yes. As of Q4 2025, Perceptive Advisors holds 692,441 shares of Corvus Pharmaceuticals Inc. (CRVS) valued at $5.3M. This data comes from their SEC 13F filing.
How many hedge funds own CRVS?
5 specialist biotech hedge funds currently hold CRVS, including OrbiMed Advisors, RTW Investments, Deerfield Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy CRVS?
Perceptive Advisors's position in CRVS was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's CRVS position increasing or decreasing?
Perceptive Advisors trimmed their CRVS position in the most recent quarter, reducing by 746,154 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CRVSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →